Agilent Technologies Inc.

This committee provides the official 'revenue estimates' and technical analysis for all tax legislation, directly influencing corporate tax structures and capital investment credits. Its expertise and reports are foundational to the tax policies that profoundly affect Agilent's financial planning and profitability.

This powerful committee controls taxation and trade policy, which directly impacts Agilent's profitability, global supply chain, and market access. Decisions on corporate tax rates, R&D credits, and international trade agreements are highly relevant to Agilent's financial performance and operations.

This committee directly allocates discretionary federal spending. Its subcommittees determine the precise budgets for agencies like NIH, EPA, FDA, and DoD, which are significant customers or provide crucial research funding that Agilent Technologies relies upon.

This committee directly regulates the FDA and oversees the NIH, both crucial for Agilent. FDA regulations for drug approval and diagnostic devices heavily influence Agilent's pharmaceutical, biotech, and clinical diagnostics customers. NIH funding is a primary driver of academic and biomedical research, a core market for Agilent.

Agilent Technologies is a major provider of analytical instruments used for environmental testing and monitoring. Regulations from the EPA, overseen by this committee, directly drive demand for Agilent's products and services in areas like water, air, and chemical analysis.